{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.0","value":"113"},{"comment":"For 1 subject in cohort 2, all plasma concentrations and all PK parameters on Cycle 1 Day 7 were excluded from the calculation of descriptive statistics because the subject was administered an unplanned dose (210 mg) on Cycle 1 Day 2, which might affect the assessment of ASTX660 PK results for the planned dose (150 mg) on Cycle 1 Day 7","groupId":"OG001","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.0","value":"64.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Day 7"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Assessment of pharmacokinetic parameter clearance of drug from plasma.","dispersionType":"Standard Deviation","groups":[{"description":"ASTX660 120mg was orally administered once a day for 7 consecutive days every other week of each 28-day cycle (ie, \\[7 days on/ 7 days off\\] ×2; daily dosing on Days 1-7 and 15-21).","id":"OG000","title":"Cohort 1"},{"description":"ASTX660 150mg was orally administered once a day for 7 consecutive days every other week of each 28-day cycle (ie, \\[7 days on/ 7 days off\\] ×2; daily dosing on Days 1-7 and 15-21).","id":"OG001","title":"Cohort 2"}],"paramType":"MEAN","populationDescription":"PK analysis population included subjects who received at least 1 dose of IMP and had available ASTX660 concentration measurement data for at least 1 time point.","reportingStatus":"POSTED","timeFrame":"Day1: pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 24hours post-dose, Day7: pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 24, 48, 72 hours post-dose","title":"Pharmacokinetic Outcome of Clearance of Drug From Plasma","type":"SECONDARY","unitOfMeasure":"L/h"}